

Docket Number: 037003-0277847

Client Reference: 1998-30-0523VUS



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of ANTONIO J GRILLO-LOPEZ      Group Art Unit: 1643

Application No.: 09/762,587

Examiner: Minh Tam B DAVIS

Filed: February 9, 2001

Confirmation No.: 5272

For: COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING  
ADMINISTRATION OF ANTI-CD20 ANTIBODY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR 1.97(e)(2).

Please charge Deposit Account 033975 in the amount of \$180.00 in payment of the fee under 37 CFR 1.17(p). Please credit or debit Deposit Account 033975 as needed to ensure consideration of the disclosed information. Two duplicated copies of this paper are attached.

Respectfully Submitted,



Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40944  
Customer Number: 5272

Date: October 3, 2003  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/JBM:ntb

Atty. Dkt. No.	M#	Client Ref.
	0277847	1998-30-0523VUS

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Applicant: Antonio GRILLO-LOPEZ

Appln. No.: 09/762,587

Filing Date: August 11, 1999

Examiner: M.T.B. Davis

Group Art Unit: 1642

Date: October 3, 2003

Page

1

of

3

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 6,306,393	10/2001	Goldenberg			
	BR 6,183,744	02/2001	Goldenberg			
	CR					
	DR					

## **FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
	ER							
	FR							

## **OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

GR	Witzig et al., "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma," <i>J Clin Oncol</i> , 2002, 20:2453-2463.				
HR	Petryk et al., "Hematologic Malignancies," <i>The Oncologist</i> , 2001, 6:317-326.				
IR	Anderson et al., "Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma," <i>Biochem Soc Trans</i> , 1997, 25:705-708.				
JR	Colombat et al., "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation," <i>Blood</i> , 2001, 97:101-106.				
KR	Coiffier et al., "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study," <i>Blood</i> , 1998, 92:1927-1932.				
LR	Endo, [Current status of nuclear medicine in Japan], <i>Gan To Kagaku Ryoho</i> , 1999, 26:744-748.				
MR	Foran et al., "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma," <i>J Clin Oncol</i> , 2000, 18:317-324.				
NR	Hainsworth et al., "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma," <i>Blood</i> , 2000, 95:3052-3056.				
OR	Maloney et al., "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> , 1997, 90:2188-2195.				
PR	McLaughlin et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," <i>J Clin Oncol</i> , 1998, 16:2825-2833.				
QR	Piro et al., "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma," <i>Ann Oncol</i> , 1999 10:655-661. (abstract only)				

RR	Davis et al., "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab," <i>J Clin Oncol</i> , 1999 17(6):1851-1857.				
SR	Byrd et al., "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity," <i>J Clin Oncol</i> , 2001, 19(8):2153-2164.				
TR					
UR					
VR					
WR					

Examiner	Date Considered:
----------	------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

